Biogen Gives Sage Therapeutics $1.5 Billion In Deal To Develop Depression And Tremor Treatments

Neurological disease treatment and therapy provider Biogen has joined with biopharmaceutical company Sage Therapeutics to develop and sell Zuranolone and SAGE-324. Joining Biogen’s neuroscience capabilities and Sage’s knowledge in psychiatry will result in needed treatments as about 17 million individuals in the United States struggle with psychiatric disorders...